04:33 PM EDT, 07/09/2025 (MT Newswires) -- Personalis ( PSNL ) , the developer of the NeXT Personal tumor-informed minimal residual disease test, expanded its collaboration with Tempus AI ( TEM ) to introduce the assay for detecting recurrence in colorectal cancer patients.

The partnership was extended to November 2029 and lengthened the period of Tempus AI's ( TEM ) exclusivity for all indications under the agreement through 2028, Personalis ( PSNL ) said Wednesday in a statement.

The addition of colorectal cancer to the exclusive commercialization agreement follows interim study results showing a "strong performance" in detecting early signs of residual or recurrent disease, Personalis ( PSNL ) said.

Personalis ( PSNL ) shares jumped 11% in recent after-hours trading, and Tempus eased 0.2%.